Day: June 4, 2021

NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center (“MSK”) and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma (“DIPG”) at the American Society of Clinical Oncology (“ASCO”) Virtual Annual Meeting on June 4, 2021 The phase 1 dose-escalation study with administration via convection enhanced delivery (“CED”), showed that dosing of omburtamab radiolabeled with 8 mCi of 124-Iodine appeared to be well-tolerated and provided distribution volume to potentially...

100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ (U2) + TG-1701 cohort (n=19) resulted in 79% ORR, with 21% CR rate, including 100% ORR in patients WM, CLL, MZL, MCL, and DLBCL (n=11) NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company’s novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ® (umbralisib), the Company’s once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsed/refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Data from this trial were made available on demand...

Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after prior systemic therapy1Additional Phase II data presented at ASCO showed tislelizumab demonstrated durable anti-tumor activity in patients with microsatellite instability-high, or mismatch-repair-deficient, solid tumors2Basel, June 4, 2021 — Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor tislelizumab improved overall survival (OS) versus chemotherapy (median 8.6 months vs. 6.3 months, p=0.0001).1 The study evaluated tislelizumab in patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma...

– INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell, and ovarian cancers and soft tissue sarcomas – – SELECT TISvopra positivity rate for patient selection in-line with projections, clinical data on-track for 2022 – CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today presented two trial in progress posters, on the Phase 1 INNATE clinical trial and the Phase 2 SELECT clinical trial, at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. INNATE, a proof-of-concept (POC) trial, is evaluating Jounce’s lead macrophage program JTX-8064...

CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade 3 TRAE Diarrhea at Doses Below 150mg BID; No Grade 3 Rash TRAEsObjective Responses Were Observed Across the Dose Range, with a Confirmed Objective Response Rate of 46% in Patients Treated at 100 mg BIDPhase 2a Expansion Initiated at 100 mg BIDCAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), an oncology company seeking to drive shareholder returns by focusing on the patient, today announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations. CLN-081 is an orally...

Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th cutoff date Monotherapy dose expansion and anti-PD-1 antibody combination parts of study expected to start in 2H 2021REDWOOD CITY, Calif., June 04, 2021 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that a poster presentation discussing preliminary data from the Phase 1/2 clinical trial of BDC-1001, Bolt’s lead candidate, was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, being held virtually from June 4-8, 2021. The poster...

Presentation on Wednesday, June 9th at 3:00 PM EDT Los Angeles, California, June 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Troika Media Group, Inc. (Nasdaq:TRKA) (“TMG” or “Company”), a brand consultancy and marketing innovations company that provides integrated branding and marketing solutions for global brands, today announced that it will be presenting virtually at the 2021 LD Micro Invitational XI investor conference on Wednesday, June 9th at 3:00 PM EDT. TMG CEO, Robert Machinist, and Kyle Hill, President of Redeeem and Head of Digital Assets for TMG, will be presenting. Register here:  https://ldmicrojune2021.mysequire.com/ Mr. Machinist will provide an overview of TMG’s strategy to be an end-to-end brand solutions company that offers integrated branding, communication, media and data analytics...

Pigeon Forge, TN, June 04, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — KYN Capital Group, Inc. (OTC: KYNC) presents Koinfoldpay, a contactless crypto payment gateway for businesses. Koinfoldpay allows your business to receive Bitcoin, Ethereum, Bitcoin Cash, and Litecoin for online payments. If you’re an eCommerce business or freelancer you will gain a competitive edge by enabling cryptocurrency payments on your invoices. Koinfoldpay enables you to seamlessly receive cryptocurrency payments, giving you an advantage and market share today and for years to come. Crypto is the future, as is Koinfoldpay. “Koinfoldpay is very unique and disruptive. This is cutting-edge technology. With the massive growth in crypto, there will be a tremendous demand for crypto payments. We are in a very unique position with our early entry...

Mean treatment free remission 1.1 years and remains ongoing Progression free survival for MYD88 wild type and high-risk patients 18 months and ongoing FLORHAM PARK, N.J., June 04, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today presented a poster at the American Society of Clinical Oncology (ASCO) Annual meeting. In conjunction with the poster presentation, management will host a KOL call with the lead investigator for the company’s Phase 2 CLOVER-1 study of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers, Dr. Sikander Ailawadhi, M.D. of the Mayo Clinic. The poster presentation entitled: Treatment Free Remission (TFR) and Overall Response Rate (ORR) Results...

Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapy Oral, once-daily 350mg dose selected for Phase 2 Enrollment of tumor-specific expansion cohorts is ongoingCAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) — Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209, a novel, second-generation, small molecule inhibitor of Enhancer of Zeste Homolog 2 (EZH2). These data were published online in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting, and show comprehensive target engagement and durable exposure of CPI-0209. Anti-tumor activity...